Skip to content
Inciteful Med

Biology & Genetics: Understanding DUX4, FSHD1, and FSHD2

Last updated:

FSHD is caused by the abnormal activation of the DUX4 gene in muscle cells. This produces a toxic protein that destroys muscle tissue. While FSHD1 and FSHD2 have different genetic triggers, both result in the same DUX4 toxicity and cause identical muscle weakness in the face, shoulders, and arms.

Key Takeaways

  • • FSHD is driven by the abnormal production of the DUX4 protein, which is toxic to skeletal muscle cells and leads to muscle death.
  • • FSHD1 is the most common form of the disease and is caused by a shortened D4Z4 repeat array combined with a 4qA haplotype.
  • • FSHD2 is rarer and caused by mutations in genes like SMCHD1 that fail to keep the DUX4 gene safely silenced.
  • • Despite having different genetic causes, FSHD1 and FSHD2 result in the exact same symptoms and pattern of muscle weakness.
  • • Up to 30 percent of FSHD cases occur spontaneously in people with absolutely no family history of the condition.

The biology of FSHD can be complex, but it essentially boils down to a single “bad actor”—a protein called DUX4. In most people, the gene that produces DUX4 is active only during the very earliest stages of embryonic development and is then permanently “silenced” or locked away for the rest of their lives [1][2]. In FSHD, this silence is broken, and DUX4 “awakens” in skeletal muscle cells where it does not belong [2][3].

The Root Cause: DUX4 Toxicity

When DUX4 is mistakenly produced in muscle cells, it acts like a toxin. It triggers a cascade of damage that leads to:

  • Muscle Cell Death: It activates a “self-destruct” program in muscle fibers [4][5].
  • Oxidative Stress: It makes muscle cells more vulnerable to damage from normal metabolic processes [6][7].
  • Fatty Replacement: As muscle cells die, the body often replaces them with fat and scar tissue (fibrosis), which cannot contract or provide strength [4][8].

The Two Paths to FSHD

There are two genetic ways the DUX4 gene can be accidentally “unlocked.” While the genetic “keys” are different, the result—the toxic DUX4 protein—is the same [9][10]. To see how this is measured on your lab report, see Confirming FSHD.

1. FSHD1 (The “Shortened Array” Type)

FSHD1 is the most common form, accounting for about 95% of cases [11][12].

  • The Mechanism: On chromosome 4, there is a region called the D4Z4 repeat array. Most people have 11 to 100 of these repeats, which keeps the DUX4 gene tightly locked and silent [13].
  • The Contraction: In FSHD1, a person has only 1 to 10 repeats [13]. This shortened array isn’t “heavy” enough to keep the gene locked, allowing DUX4 to be expressed [14][15].
  • The Permissive Haplotype (4qA): To actually get the disease, you must also have a specific genetic “tail” called the 4qA haplotype [3]. This tail stabilizes the DUX4 message, allowing it to survive long enough to create the toxic protein [16][15].

2. FSHD2 (The “Modifier Mutation” Type)

FSHD2 is rarer, affecting about 5% of patients [9].

  • The Mechanism: In FSHD2, the D4Z4 repeat array is typically a normal length (11 to 20 repeats) [17]. However, the “locking mechanism” itself is broken [11].
  • The Mutations: This is usually caused by a mutation in a different gene, most commonly SMCHD1 (or sometimes DNMT3B) [18][19]. These genes are responsible for maintaining the “silence” of DUX4. When they don’t work, DUX4 awakens even without a shortened repeat array [20][21].

Are FSHD1 and FSHD2 Different?

From a patient’s perspective, FSHD1 and FSHD2 are virtually identical in terms of how they look and act [9][1]. Both cause the same pattern of asymmetric muscle weakness in the face, shoulders, and arms [22].

Inheritance and Family Planning

The main difference lies in how they are inherited [23].

  • FSHD1 is Autosomal Dominant: This means an affected parent has a 50% chance of passing the condition to each of their children [11].
  • FSHD2 is Digenic: It requires inheriting two different genetic factors to manifest, making the inheritance pattern more complex [23].
  • Spontaneous (De Novo) Mutations: It is highly important to note that 10% to 30% of FSHD cases are “de novo” [24][25]. This means the genetic mutation occurred spontaneously in the patient, and there is absolutely no family history of the disease. If you are the first in your family to be diagnosed, this is likely why.

Because of the genetic nature of FSHD, it is strongly recommended that patients and their families speak with a Genetic Counselor. They can help you understand the exact statistical odds of passing the disease on and discuss family planning options, such as Preimplantation Genetic Testing (PGT) during IVF, to ensure your children do not inherit the condition [26].

Frequently Asked Questions

What is the main cause of FSHD?
FSHD is primarily caused by the abnormal awakening of the DUX4 gene in skeletal muscle cells. When this gene produces the DUX4 protein in muscles, it acts like a toxin that causes muscle cell death and progressive weakness.
What is the difference between FSHD1 and FSHD2?
Both types lead to the same muscle weakness caused by the DUX4 protein, but they happen for different genetic reasons. FSHD1 is caused by a shortened DNA section called the D4Z4 repeat array, while FSHD2 is usually caused by a mutation in a different gene that fails to keep DUX4 locked away.
Can I get FSHD if no one else in my family has it?
Yes, about 10 to 30 percent of FSHD cases happen spontaneously. This means the genetic mutation occurred randomly in you, even if there is absolutely no family history of the disease.
What does a 4qA haplotype mean on my FSHD lab report?
The 4qA haplotype is a specific genetic marker that allows the toxic DUX4 protein to survive long enough to damage muscle cells. You must have this specific genetic tail in addition to the shortened repeat array to actually develop FSHD1.
Why should I speak with a genetic counselor about FSHD?
Because FSHD is a genetic condition, a genetic counselor can help you understand your specific test results, explain the statistical odds of passing the disease to your children, and discuss family planning options like preimplantation genetic testing.

Questions for Your Doctor

  • • Based on my genetic testing, do I have FSHD1 or FSHD2, and what are the specific implications for my children?
  • • Is my 4qA status (the permissive haplotype) confirmed on my report?
  • • Since DUX4 is the common cause for both types, are there specific clinical trials targeting DUX4 that you would recommend I watch?
  • • How does my D4Z4 repeat count correlate with the degree of muscle cell damage you are seeing?

Questions for You

  • • Have I spoken with a genetic counselor to understand how FSHD1 or FSHD2 might be passed down in my family?
  • • Am I experiencing signs of muscle inflammation, such as unusual soreness or a heavy feeling in my shoulders and face?
  • • Does knowing that the cause of FSHD is a single "misbehaving" protein (DUX4) change how I think about future treatment possibilities?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

    Greco A, Goossens R, van Engelen B, van der Maarel SM

    Clinical genetics 2020; (97(6)):799-814 doi:10.1111/cge.13726.

    PMID: 32086799
  2. 2

    Genetic and epigenetic contributors to FSHD.

    Daxinger L, Tapscott SJ, van der Maarel SM

    Current opinion in genetics & development 2015; (33()):56-61.

    PMID: 26356006
  3. 3

    A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.

    Gatica LV, Rosa AL

    Neuromuscular disorders : NMD 2016; (26(12)):844-852 doi:10.1016/j.nmd.2016.09.015.

    PMID: 27816329
  4. 4

    MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.

    Runfola V, Giambruno R, Caronni C, et al.

    Cell reports 2023; (42(9)):113120 doi:10.1016/j.celrep.2023.113120.

    PMID: 37703175
  5. 5

    Downstream events initiated by expression of FSHD-associated DUX4: Studies of nucleocytoplasmic transport, γH2AX accumulation, and Bax/Bak-dependence.

    Masteika IF, Sathya A, Homma S, et al.

    Biology open 2022; (11(2)) doi:10.1242/bio.059145.

    PMID: 35191484
  6. 6

    Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.

    Lek A, Zhang Y, Woodman KG, et al.

    Science translational medicine 2020; (12(536)) doi:10.1126/scitranslmed.aay0271.

    PMID: 32213627
  7. 7

    A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.

    Sasaki-Honda M, Jonouchi T, Arai M, et al.

    Human molecular genetics 2018; (27(23)):4024-4035 doi:10.1093/hmg/ddy293.

    PMID: 30107443
  8. 8

    It's not all about muscle: fibroadipogenic progenitors contribute to facioscapulohumeral muscular dystrophy.

    Serra C, Wagner KR

    The Journal of clinical investigation 2020; (130(5)):2186-2188.

    PMID: 32250345
  9. 9

    Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.

    Jia FF, Drew AP, Nicholson GA, et al.

    Neuromuscular disorders : NMD 2021; (31(11)):1101-1112 doi:10.1016/j.nmd.2021.09.010.

    PMID: 34711481
  10. 10

    Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy in Patients Clinically Suspected of FSHD Using Optical Genome Mapping.

    Guruju NM, Jump V, Lemmers R, et al.

    Neurology. Genetics 2023; (9(6)):e200107 doi:10.1212/NXG.0000000000200107.

    PMID: 38021397
  11. 11

    Facioscapulohumeral Muscular Dystrophy.

    Statland JM, Tawil R

    Continuum (Minneapolis, Minn.) 2016; (22(6, Muscle and Neuromuscular Junction Disorders)):1916-1931 doi:10.1212/CON.0000000000000399.

    PMID: 27922500
  12. 12

    Facioscapulohumeral Muscular Dystrophy.

    DeSimone AM, Pakula A, Lek A, Emerson CP

    Comprehensive Physiology 2017; (7(4)):1229-1279 doi:10.1002/cphy.c160039.

    PMID: 28915324
  13. 13

    New Insights into Genotype-phenotype Correlations in Chinese Facioscapulohumeral Muscular Dystrophy: A Retrospective Analysis of 178 Patients.

    Lin F, Wang ZQ, Lin MT, et al.

    Chinese medical journal 2015; (128(13)):1707-13 doi:10.4103/0366-6999.159336.

    PMID: 26112708
  14. 14

    Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.

    Haynes P, Bomsztyk K, Miller DG

    Epigenetics & chromatin 2018; (11(1)):47 doi:10.1186/s13072-018-0215-z.

    PMID: 30122154
  15. 15

    The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow.

    de la Kethulle de Ryhove L, Ansseau E, Nachtegael C, et al.

    Stem cells and development 2015; (24(22)):2674-86 doi:10.1089/scd.2014.0575.

    PMID: 26192274
  16. 16

    Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2.

    Lemmers RJ, van der Vliet PJ, Balog J, et al.

    European journal of human genetics : EJHG 2018; (26(1)):94-106 doi:10.1038/s41431-017-0015-0.

    PMID: 29162933
  17. 17

    Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.

    Renard D, Taieb G, Garibaldi M, et al.

    American journal of medical genetics. Part A 2018; (176(8)):1760-1763 doi:10.1002/ajmg.a.38843.

    PMID: 30055030
  18. 18

    Clinical, muscle pathological, and genetic features of Japanese facioscapulohumeral muscular dystrophy 2 (FSHD2) patients with SMCHD1 mutations.

    Hamanaka K, Goto K, Arai M, et al.

    Neuromuscular disorders : NMD 2016; (26(4-5)):300-8.

    PMID: 27061275
  19. 19

    Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy.

    van den Boogaard ML, Lemmers RJLF, Balog J, et al.

    American journal of human genetics 2016; (98(5)):1020-1029 doi:10.1016/j.ajhg.2016.03.013.

    PMID: 27153398
  20. 20

    DNMT3B splicing dysregulation mediated by SMCHD1 loss contributes to DUX4 overexpression and FSHD pathogenesis.

    Engal E, Sharma A, Aviel U, et al.

    Science advances 2024; (10(22)):eadn7732 doi:10.1126/sciadv.adn7732.

    PMID: 38809976
  21. 21

    SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells.

    Huang Z, Cui W, Klaiss A, Pfeifer GP

    bioRxiv : the preprint server for biology 2026; doi:10.64898/2026.02.21.707202.

    PMID: 41756954
  22. 22

    Generation of a transgene-free iPSC line and genetically modified line from a facioscapulohumeral muscular dystrophy type 2 (FSHD2) patient with SMCHD1 p.Lys607Ter mutation.

    Sasaki-Honda M, Kagita A, Jonouchi T, et al.

    Stem cell research 2020; (47()):101884 doi:10.1016/j.scr.2020.101884.

    PMID: 32711388
  23. 23

    CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.

    Rieken A, Bossler AD, Mathews KD, Moore SA

    Neurology 2021; (96(7)):e1054-e1062 doi:10.1212/WNL.0000000000011412.

    PMID: 33443126
  24. 24

    Combined Lumbar-Sacral Plexus Block in Facioscapulohumeral Muscular Dystrophy for Hip Fracture Surgery: A Case Report.

    Manici M, Kalyoncu İ, Gedik CC, et al.

    Turkish journal of anaesthesiology and reanimation 2024; (52(1)):36-38 doi:10.4274/TJAR.2024.231471.

    PMID: 38414180
  25. 25

    Meeting report: the 2021 FSHD International Research Congress.

    Jagannathan S, de Greef JC, Hayward LJ, et al.

    Skeletal muscle 2022; (12(1)):1 doi:10.1186/s13395-022-00287-8.

    PMID: 35039091
  26. 26

    Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.

    Vincenten SCC, Van Der Stoep N, Paulussen ADC, et al.

    Clinical genetics 2022; (101(2)):149-160 doi:10.1111/cge.14031.

    PMID: 34297364

This page explains the genetics of FSHD for educational purposes only. Always consult a genetic counselor or neurologist to help interpret your specific genetic test results and understand your family's inheritance risks.

Stay up to date

Get notified when new research about Facioscapulohumeral dystrophy is published.

No spam. Unsubscribe anytime.